MyFinsight
Home
Blog
About
Product
$235,794K
(69.83%↑ Y/Y)
License
$4,541K
Revenue
$240,335K
(70.27%↑ Y/Y)
Operating income
$21,674K
(-37.80%↓ Y/Y)
Total costs and
expenses
$218,661K
(105.69%↑ Y/Y)
Net income before
taxes
$10,234K
(-66.90%↓ Y/Y)
Total other expense
-$11,440K
(-191.61%↓ Y/Y)
Other income
$5,132K
(83.75%↑ Y/Y)
Total research and
development
$95,337K
(199.97%↑ Y/Y)
Total selling,
general and...
$82,130K
(47.76%↑ Y/Y)
Cost of revenue
$41,194K
(117.52%↑ Y/Y)
Net income
$7,781K
(-72.40%↓ Y/Y)
Income tax expense
$2,453K
(-10.25%↓ Y/Y)
Interest expense
$16,572K
(146.75%↑ Y/Y)
Other research and
development
$87,267K
(217.75%↑ Y/Y)
Stock-based compensation
$8,070K
(86.89%↑ Y/Y)
Other selling,
general and...
$62,325K
(43.14%↑ Y/Y)
Stock-based compensation
$19,805K
(64.44%↑ Y/Y)
Back
Back
Income Statement
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
source: myfinsight.com